A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration (NCT05230537)
A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Macular Degeneration
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
Who can join: Review the eligibility criteria below.
Location: Retina Consultants of Orange County — Fullerton, California
Age range: 50 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (28 Sites)
Showing the first 25 of 28 sites.
- Retina Consultants of Orange County — Fullerton, California
- Salehi Retina Institute — Huntington Beach, California
- Martel Eye Medical Group — Rancho Cordova, California
- Retinal Consultants Medical Group Inc — Sacramento, California
- California Retina Consultants — Santa Barbara, California
- Southwest Retina Research Center — Durango, Colorado
- Advanced Research LLC — Deerfield Beach, Florida
- Retina Center Of South Florida — Delray Beach, Florida
- Retina Vitreous Associates of Florida — St. Petersburg, Florida
- Midwest Eye Institute — Indianapolis, Indiana
- Retina Associates New Orleans — New Orleans, Louisiana
- Retina Care Center — Baltimore, Maryland
- Opthamalic Consultants of Boston — Boston, Massachusetts
- Envision Ocular LLC — Bloomfield, New Jersey
- Duke Eye Center — Durham, North Carolina
- Retina Northwest PC — Portland, Oregon
- Charles Retina Institute — Germantown, Tennessee
- Austin Research Center for Retina — Austin, Texas
- Retina Consultants TX Rsrch Ctr — Bellaire, Texas
- Retina Foundation — Dallas, Texas
- Texas Retina Associates — Fort Worth, Texas
- Retina Consultants of Houston PA — Houston, Texas
- Novartis Investigative Site — Harbin, Heilongjiang
- Novartis Investigative Site — Tianjin, Tianjin Municipality
- Novartis Investigative Site — Shanghai,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Age-Related Macular Degeneration
- A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders — Springfield, Illinois
- Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration — San Francisco, California
- ForeseeHome NRich Registry — Toms River, New Jersey
- Impact of Non-Exudative Type 1 MNV on AMD Progression — Salt Lake City, Utah
- A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration — Phoenix, Arizona
- Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration — Scottsdale, Arizona
Explore by condition: All Age-Related Macular Degeneration clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.